Avian influenza viruses (AIV) remain prevalent among wild bird populations in the European Union and European Economic Area (EU/EEA), leading to significant illness in and death of birds.
Injected trivalent inactivated influenza vaccines are most commonly used throughout the world. Influenza antigen preparation varies between manufacturers.
Risks of an adverse event following influenza vaccination are far less common than complications related to influenza itself, and the adverse events are generally localised and mild.
Between 2 December 2023 and 15 March 2024, highly pathogenic avian influenza (HPAI) A(H5) outbreaks were reported in domestic (227) and wild (414) birds across 26 countries in Europe.
Every month ECDC provides detailed epidemiological overview of the worldwide transmission of chikungunya in its weekly threat report (Communicable Diseases Threat Report).